A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children

Abstract

Recently a framework was presented to assess whether pediatric covariate models for clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio, protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for midazolam clearance can be used to scale clearance of other CYP3A substrates. A population PK model including a covariate function for clearance was developed for midazolam in children aged 1–17 years. Commonly used CYP3A substrates were selected and using the framework, it was assessed whether the midazolam covariate function accurately scales their clearance. For eight substrates, reported pediatric clearance values were compared numerically and graphically with clearance values scaled using the midazolam covariate function. For sildenafil, clearance values obtained with population PK modeling based on pediatric concentration-time data were compared with those scaled with the midazolam covariate function. According to the framework, a midazolam covariate function will lead to systemically accurate clearance scaling (absolute prediction error (PE) < 30%) for CYP3A substrates binding to albumin with an extraction ratio between 0.35 and 0.65 when binding < 10% in adults, between 0.05 and 0.55 when binding > 90%, and with an extraction ratio ranging between these values when binding between 10 and 90%. Scaled clearance values for eight commonly used CYP3A substrates were reasonably accurate (PE < 50%). Scaling of sildenafil clearance was accurate (PE < 30%). We defined for which CYP3A substrates a pediatric covariate function for midazolam clearance can accurately scale plasma clearance in children. This scaling approach may be useful for CYP3A substrates with scarce or no available pediatric PK information. Electronic supplementary material The online version of this article (10.1208/s12248-019-0351-9) contains supplementary material, which is available to authorized users.

The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study

“…Recently, a framework was published for between-drug extrapolation of covariate models 55 which was used by Brussee et al to study whether scaling with a pediatric covariate function from midazolam will lead to accurate clearance values of other CYP3A substrates. 56 Clearances of drugs were accurately scaled when they were mainly eliminated by CYP3A-mediated metabolism with, for example, high protein binding to albumin (> 90%) and a low-to-intermediate extraction ratio of < 0.55 in adults. However, the covariate relationship for clearance was based on data from children > 1 year of age.…”

Sedation level with midazolam: A pediatric surgery approach

“…On the other hand, there are few studies reported in the literature about clinical trials using a MDZ pediatric population model ( Brussee et al, 2019 , de Wildt et al, 2003 , van Groen et al, 2019 , Vet et al, 2016 , Völler et al, 2019 ), which have contributed to this type of population pharmacotherapy within the hospital environment.…”

Drug–drug and drug–food interactions in an infant with early‐onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet

“…Although the same CBZ formulation was administered at fix times, we cannot exclude potential additional variations in absorption associated with varying feeding times (child nourished ad libitum). While we accounted for expected increases in clearance and volume of distribution with weight by standard allometric scaling (with a close estimate of 0.874 proposed for the CYP3A4 reference drug midazolam 37 ) we cannot exclude additional or confounding age‐dependent changes.…”